# PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

> **NCT03307512** · PHASE2 · TERMINATED · sponsor: **Dance Biopharm Inc.** · enrollment: 40 (actual)

## Conditions studied

- Safety and Tolerability

## Interventions

- **DRUG:** inhaled human insulin
- **DRUG:** Insulin Lispro (Humalog U-100)

## Key facts

- **NCT ID:** NCT03307512
- **Lead sponsor:** Dance Biopharm Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-06
- **Primary completion:** 2019-07-30
- **Final completion:** 2019-08-30
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Termination due to incomplete enrollment; planned data analysis not performed
- **Last updated:** 2019-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03307512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03307512, "PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03307512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*